Skip to main content

Table 3 Risk factors of overall survival in HCC patients with MVI who received one-shot CDDP plus RT

From: Efficacy and safety of chemoradiation therapy using one-shot cisplatin via hepatic arterial infusion for advanced hepatocellular carcinoma with major macrovascular invasion: a single-arm retrospective cohort study

Parameter

Univariate analysis

Multivariate analysis

p value

OR

95% CI

p value

Age (≥ 65/ < 65 years)

0.303

   

Gender (female/male)

0.599

   

Etiology (with viral hepatitis/without viral hepatitis)

0.528

   

ECOG- Performance Status (0/ ≥ 1)

0.924

   

Albumin (≥ 3.5/ < 3.5 g/dL)

0.692

   

Prothrombin consumption test (≥ 70%/ < 70%)

0.789

   

Child–Pugh score (6 ≥ /5)

0.619

   

mALBI grade (≥ 2b/ ≤ 2a)

0.129

   

Diameter of main tumor (≥ 70/ < 70 mm)

0.11

   

Number of tumors in the liver (≥ 4/ < 4)

0.478

   

Relative tumor volume in the liver (≥ 50%/ < 50%)

0.011

4.501

1.61–12.59

0.041

Vp (3/4)

0.801

   

Vv (with/without)

0.539

   

Extrahepatic spread (with/without)

0.077

  

0.367

Alpha-fetoprotein (≥ 400/ < 400 ng/mL)

0.048

  

0.403

Des-γ-carboxy prothrombin (≥ 400/ < 400 mAU/mL)

0.694

   

First response of MVI (SD or PD/ CR or PR)

0.002

7.396

2.639–20.72

 < 0.001

  1. Univariate and multivariate analysis of risk factor of overall survival in HCC patients with MVI who received one-shot CDDP chemotherapy via HAI plus RT. HCC hepatocellular carcinoma; MVI macrovascular invasion; CDDP cisplatin; RT radiation therapy; OR odds ratio; CI confidence interval; ECOG-Performance Status Eastern Cooperative Oncology Group Performance Status; ALBI score = log10([total-bilirubin(mg/dL)]*17.1*0.66 − [albumin(g/dL)]*10*0.085; mALBI grade 1: 2a: 2b: 3 = ALBI score ≤  − 2.6: >  − 2.6 to <  − 2.27: ≥  − 2.27 to ≤  − 1.39: >  − 1.39; Vp portal vein invasion; Vv venous invasion; SD stable disease; PD progressive disease; CR complete response; PR partial response; HAI hepatic arterial infusion